The number of tumor-infiltrating CD8+ T cells was significantly increased in combination therapy (Figure 6), suggesting that OBP-702 has therapeutic potential to promote the anti-tumor immune response against PDAC tumors. The gene discussed is CD8A; the disease is neoplasm.